Bora Pharmaceuticals acquires GSK Mississauga facility
The transaction is expected to be complete by the end of 2020
Bora Pharmaceuticals Co. Ltd. and fellow pharma manufacturer GlaxoSmithKline (GSK) announced on March 9 that they have entered into an agreement under which Bora Pharmaceuticals will acquire GSK’s Mississauga, Ont.-based facility.
The GSK facility employs approximately 400 manufacturing staff who will be invited to join Bora Pharmaceuticals as part of the transaction. Bora Pharmaceuticals will continue to manufacture, under contract, the existing GSK product line for a minimum of five years.
“We are excited to announce the next phase of our expansion into North America with the acquisition of this world-class facility and we look forward to welcoming the Mississauga manufacturing employees, whom we view as the most significant asset in this transaction, into our business,” Bobby Sheng, CEO of Bora Pharmaceuticals, said in a prepared statement. “The Mississauga-based facility is ideally suited with our intention to grow our technical capabilities and scale in the global contract development and manufacturing organization (CDMO) marketplace.”
Andrew Ehrat, Mississauga site director for GSK in Canada said, “We expect to complete the transaction no later than the end of 2020, and in the meantime, we remain wholly committed to maintaining a business which runs safely and efficiently in the best interest of patients.”
Subject to the appropriate regulatory clearances, the transaction will see the ownership of the entire GSK Mississauga site – including all facilities – transfer over to Bora Pharmaceuticals. GSK employees in the Pharmaceuticals and Consumer Healthcare commercial businesses, who currently work in office space at the Mississauga site, will move to new locations within an agreed timeframe following the close of the transaction.